3SBIO (01530) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
cls.cnNov 26 21:39 ET
Hong Kong stocks are moving differently | Most pharmaceutical stocks are rising as the results of the medical insurance negotiations are about to be revealed. Institutions indicate that the sector still has further room for recovery.
Most pharmaceutical stocks are rising, as of the deadline, Keji Pharmaceutical-B (02171) rose by 12.38%, to 7.71 Hong Kong dollars; innocare (09969) rose by 5.36%, to 6.49 Hong Kong dollars; Kainuo Ya-B (02162) rose by 4.3%, to 41.25 Hong Kong dollars.
Zhitong FinanceNov 26 20:47 ET
3SBio's Unit Gets Exclusive Commercialization Rights for Clifutinib Besylate in Mainland China
MT NewswiresNov 26 04:02 ET
3SBio Partners With Sunshine Lake Pharma for Drug Rights
TipRanksNov 25 05:17 ET
3sbio (01530.HK): Shenyang 3sbio and guangdong hec technology holding reached a cooperation on sulfonamic acid clifene.
Gelonghui November 25th | 3sbio (01530.HK) announced that its subsidiary Shenyang 3sbio Pharmaceutical Co., Ltd. has reached a cooperation agreement with Guangdong Hec CJ Pharm Co., Ltd. and its subsidiary Yichang Hec CJ Pharm Co., Ltd. on the commercialization of specific indications of Benzoate Crizotinib. According to the agreement, Shenyang 3sbio will obtain the exclusive commercialization rights of Crizotinib specific indications under the product portfolio of Guangdong Hec CJ Pharm in mainland China. Shenyang 3sbio will make the initial payment and corresponding R&D and sales milestone payments to Guangdong Hec CJ Pharm as agreed in the agreement. Guangdong Hec CJ Pharm will continue to be responsible for the Crizotinib
Gelonghui FinanceNov 25 05:03 ET
Express News | 3Sbio - Cooperation Between Shenyang Sunshine and Sunshine Lake Pharma in Respect of Clifutinib Besylate
ReutersNov 25 05:01 ET

Comments

Bull X Bear

Oct 3 02:14

What would you buy in your Hong Kong portfolio?

Banks: $ABC (01288.HK)$ $BANK OF CHINA (03988.HK)$
Securities & Brokerage: $HTSC (06886.HK)$ $CMSC (06099.HK)$
Gaming Software: $NTES-S (09999.HK)$ $XD INC (02400.HK)$ $NETDRAGON (00777.HK)$
Digital Solutions: $TENCENT (00700.HK)$ $TRAVELSKY TECH (00696.HK)$ $CHINASOFT INT'L (00354.HK)$
Online Retailer: $BABA-W (09988.HK)$ $MEITUAN-W (03690.HK)$ $JD-SW (09618.HK)$
Insurer: $PING AN (02318.HK)$ $AIA (01299.HK)$ $CHINA LIFE (02628.HK)$
Telecommunication: $CHINA MOBILE (00941.HK)$ $CHINA TELECOM (00728.HK)$
...

Officials say the real estate market is bottoming out. What’s your view on China's property market?

15

7

Moomoo AI

Mar 17 20:08

3SBio Inc.'s lower P/E ratio is due to its forecasted growth being less than the wider market. The potential for earnings improvement may not justify a higher P/E ratio, forming a barrier for the share price.

Investors Don't See Light At End Of 3SBio Inc.'s (HKG:1530) Tunnel

1

Moomoo AI

Jan 24 01:50

Despite a recent drop, 3SBio's strong financials and high ROE could boost stock value long term. Significant earnings growth due to substantial profit reinvestment, though future growth may slow.

Could The Market Be Wrong About 3SBio Inc. (HKG:1530) Given Its Attractive Financial Prospects?

Moomoo AI

Dec 28, 2023 17:33

Analyst indicates that the investment risk in 3SBio is kept in check by net cash and EBIT growth. Even though managing debt could be challenging as free cash flow was only 46% of EBIT recently, the company's financials are still strong.

3SBio (HKG:1530) Seems To Use Debt Rather Sparingly

Moomoo AI

Dec 7, 2023 16:19

3SBio, with EPS growth and increased EBIT margins, is defined as a growing business. High level of insider ownership is deemed positive, aligning with shareholders' interests. Yet, the market valuation of it remains unanalysed.

3SBio (HKG:1530) Ticks All The Boxes When It Comes To Earnings Growth

01530 3SBIO

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target